How long should an intravenous (IV) infusion of Venofer (iron sucrose) be administered?

Venofer (Iron Sucrose) IV Infusion Duration

Venofer should be administered over 2 to 5 minutes as a slow IV push for doses of 100-200 mg, or over 15 minutes to 4 hours as an infusion depending on the dose and clinical setting, as specified by FDA-approved dosing protocols. 1

Standard Administration Times by Dose and Patient Population

Hemodialysis-Dependent CKD (HDD-CKD)

• 100 mg dose: Administer undiluted over 2 to 5 minutes as slow IV injection, OR dilute in maximum 100 mL 0.9% NaCl and infuse over at least 15 minutes 1
• Give early during dialysis session (generally within first hour) 1

Non-Dialysis Dependent CKD (NDD-CKD)

• 200 mg dose: Administer undiluted over 2 to 5 minutes as slow IV injection, OR dilute in maximum 100 mL 0.9% NaCl and infuse over 15 minutes 1
• 500 mg dose (limited experience): Dilute in maximum 250 mL 0.9% NaCl and infuse over 3.5 to 4 hours 1

Peritoneal Dialysis-Dependent CKD (PDD-CKD)

• 300 mg dose: Dilute in maximum 250 mL 0.9% NaCl and infuse over 1.5 hours 1
• 400 mg dose: Dilute in maximum 250 mL 0.9% NaCl and infuse over 2.5 hours 1

Pediatric Patients (≥2 years)

• 0.5 mg/kg (max 100 mg): Administer undiluted over 5 minutes, OR dilute to 1-2 mg/mL concentration in 0.9% NaCl and infuse over 5 to 60 minutes 1
• Never dilute below 1 mg/mL concentration 1

Infusion Rate and Safety Considerations

Slower infusion rates are associated with lower infusion reaction rates and should be initiated at a slow rate with close observation during the first 10 minutes, as immediate reactions typically occur within the first minute. 2

Practical Administration Evidence

• Multiple studies demonstrate that 200 mg administered as a 2-minute IV push is safe and practical in CKD patients, with 97.5% of 2,297 injections proceeding uneventfully 3
• The most common adverse event with rapid push is transient metallic taste (17.9% of cases), which causes no significant patient distress 3
• Serious anaphylactoid reactions are extremely rare (0.3% in one large series) and resolve within 30 minutes without hospitalization 3

Dose-Specific Safety Warnings

• Avoid 500 mg doses over 4 hours in females weighing <65 kg: Drug-related hypotension, including one serious event, occurred in this population 4
• Doses up to 300 mg can be safely administered within 60 minutes 5

Monitoring Requirements

All patients require observation during infusion and for at least 15 minutes after completion, with vital signs monitoring (BP, pulse, respiratory rate, O2 saturation, temperature) until stable. 2

• Immediate infusion reactions occur during the first minute of administration 2
• By 4 hours post-infusion, the likelihood of acute infusion-related adverse events is essentially negligible 6
• Educate patients on delayed reactions (flu-like symptoms, arthralgias, myalgias, fevers) manageable with NSAIDs 2

Clinical Pitfalls to Avoid

• Do not use test doses: Iron sucrose carries no black-box warning and does not require test dosing 5
• Ensure proper dilution for pediatric patients: Never dilute below 1 mg/mL concentration 1
• Time administration appropriately: For optimal hemoglobin response, administer at least 2-4 weeks before anticipated need (e.g., surgery, delivery), as peak hemoglobin occurs approximately 4 weeks post-infusion 7, 8
• Stop infusion immediately if any acute signs/symptoms develop: Notify physician and switch IV line to normal saline at keep-vein-open rate 2